Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Gene |
RCV001575905 | SCV001802996 | uncertain significance | not provided | 2023-01-31 | criteria provided, single submitter | clinical testing | In silico analysis supports that this missense variant has a deleterious effect on protein structure/function; Has not been previously published in association with disease to our knowledge; This variant is associated with the following publications: (PMID: 26435059) |
Labcorp Genetics |
RCV001575905 | SCV002311474 | uncertain significance | not provided | 2024-12-24 | criteria provided, single submitter | clinical testing | This sequence change replaces arginine, which is basic and polar, with cysteine, which is neutral and slightly polar, at codon 868 of the WFS1 protein (p.Arg868Cys). This variant is present in population databases (rs148611943, gnomAD 0.03%). This variant has not been reported in the literature in individuals affected with WFS1-related conditions. ClinVar contains an entry for this variant (Variation ID: 1207795). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt WFS1 protein function with a positive predictive value of 80%. In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. |
Fulgent Genetics, |
RCV002488403 | SCV002785439 | uncertain significance | Cataract 41; Wolfram syndrome 1; Autosomal dominant nonsyndromic hearing loss 6; Type 2 diabetes mellitus; Wolfram-like syndrome | 2024-05-18 | criteria provided, single submitter | clinical testing | |
Mayo Clinic Laboratories, |
RCV001575905 | SCV005410518 | uncertain significance | not provided | 2023-10-24 | criteria provided, single submitter | clinical testing | PP3, PM2_moderate |
Prevention |
RCV004738349 | SCV005365634 | uncertain significance | WFS1-related disorder | 2024-07-24 | no assertion criteria provided | clinical testing | The WFS1 c.2602C>T variant is predicted to result in the amino acid substitution p.Arg868Cys. To our knowledge, this variant has not been reported in the literature. This variant is reported in 0.024% of alleles in individuals of African descent in gnomAD. Alternative variant at the same codon p.Arg868His has been reported together with second WFS1 variant in patients with hearing loss (Table S2, Ma et al. 2023. PubMed ID: 36597107; Table S3, Sloan-Heggen. 2016. PubMed ID: 26969326). Other alternative variant at the same codon p.Arg868Pro has been reported in an individual with diabetes (Table S6, Yu. 2019. PubMed ID: 31264968). At this time, the clinical significance of this variant is uncertain due to the absence of conclusive functional and genetic evidence. |